Rituximab biosimilar - JHL Biotech

Drug Profile

Rituximab biosimilar - JHL Biotech

Alternative Names: JHL 1101

Latest Information Update: 11 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator JHL Biotech
  • Developer JHL Biotech; Sanofi
  • Class Antineoplastics; Antirheumatics; Monoclonal antibodies
  • Mechanism of Action Apoptosis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Rheumatoid arthritis
  • Preclinical Non-Hodgkin's lymphoma

Most Recent Events

  • 09 Jul 2018 JHL Biotech receives positive advice from CHMP of EMA for the conduction of a phase III trial in Non-Hodgkin's lymphoma
  • 05 Jul 2018 Center for Drug Evaluation, State Drug Administration of China approves phase I and phase III clinical trial application for JHL 1101 in Non-Hodgkin lymphoma
  • 22 Feb 2018 JHL Biotech plans a phase III trial in Non-Hodgkin's lymphoma in China, in 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top